Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 21
    records per page




    Comparative analysis of immune-associated genes in COVID-19, cardiomyopathy HP cardiomyopathy MESHD and venous thromboembolism MESHD thromboembolism HP

    Authors: Grant E Castaneda; Abby C Lee; Wei Tse Li; Chengyu Chen; Jaideep Chakladar; Eric Chang; Weg Ongkeko; Xiaojian Liu; Wei Gao; Renli Zhang; Qiru Su; Andrew Azman; Justin Lessler; Xuan Zou; Wenfeng Gong; Brenda Clemente; Jerel Vega; Scott Roberts; Jose A. Gonzalez; Marciano Sablad; Rodrigo Yelin; Wendy Taylor; Kiyoshi Tachikawa; Suezanne Parker; Priya Karmali; Jared Davis; Sean M Sullivan; Steve G. Hughes; Pad Chivukula; Eng Eong Ooi

    doi:10.1101/2020.08.28.20184234 Date: 2020-09-02 Source: medRxiv

    As of 28 August 2020, there have been 5.88 million Coronavirus Disease MESHD 2019 (COVID-19) cases and 181,000 COVID-19 related deaths in the United States alone. Given the lack of an effective pharmaceutical treatment for COVID-19, the high contagiousness of the disease and its varied clinical outcomes, identifying patients at risk of progressing to severe disease is crucial for the allocation of valuable healthcare resources during this pandemic. Current research has shown that there is a higher prevalence SERO of cardiovascular comorbidities amongst patients with severe COVID-19 or COVID-19-related deaths, but the link between cardiovascular disease MESHD and poorer prognosis is poorly understood. We believe that pre-existing immune dysregulation HP that accompanies cardiovascular disease MESHD predisposes patients to a harmful inflammatory immune response, leading to their higher risk of severe disease. Thus, in this project, we aim to characterize immune dysregulation HP dysregulation MESHD in patients with cardiomyopathy HP cardiomyopathy MESHD, venous thromboembolism MESHD thromboembolism HP and COVID-19 patients by looking at immune-associated gene dysregulation, immune HP infiltration and dysregulated immunological pathways and gene signatures.

    A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease MESHD

    Authors: Samarthkumar Thakkar; Shilpkumar Arora; Ashish Kumar; Rahul Jaswaney; Mohammed Faisaluddin; Mohammad Ammad Ud Din; Mariam Shariff; Kirolos Barssoum; Harsh P. Patel; Nirav Arora; Chinmay Jani; Sejal Savani; Christopher DeSimone; Siva Mulpuru; Abhishek Deshmukh

    doi:10.1101/2020.08.09.20171330 Date: 2020-08-11 Source: medRxiv

    The impact of coronavirus disease MESHD, 2019 (COVID-19), has been profound. Though COVID-19 primarily affects the respiratory system, it has also been associated with a wide range of cardiovascular (CV) manifestations portending extremely poor prognosis. The principal hypothesis for CV involvement is through direct myocardial infection MESHD and systemic inflammation MESHD. We conducted a systematic review of the current literature to provide a foundation for understanding the CV manifestations and outcomes of COVID-19. PubMed and EMBASE databases were electronically searched from the inception of the databases through April 27th, 2020. A second literature review was conducted to include major trials and guidelines that were published after the initial search but before submission. The inclusion criteria for studies to be eligible were case reports, case series, and observation studies reporting CV outcomes among patients with COVID-19 infection MESHD. This review of the current COVID-19 disease and CV outcomes literature revealed a myriad of CV manifestations with potential avenues for treatment and prevention. Future studies are required to understand on a more mechanistic level the effect of COVID-19 on the myocardium and thus provide avenues to improve mortality and morbidity.

    Cardiac involvement in COVID-19 patients: mid-term follow up by cardiac magnetic resonance imaging

    Authors: Hui Wang; Ruili Li; Hong Jiang; Zixu Yan; Xinyan Tao; Hongjun Li; Lei Xu

    doi:10.21203/rs.3.rs-57104/v1 Date: 2020-08-11 Source: ResearchSquare

    Background: Coronavirus disease MESHD 2019 (COVID-19) induces myocardial injury MESHD, either direct myocarditis HP myocarditis MESHD or indirect injury due to systemic inflammatory response. Myocardial involvement MESHD has been proved to be one of the primary manifestations of COVID-19 infection MESHD, according to laboratory test, autopsy, and cardiac magnetic resonance imaging (CMRI). However, the middle-term outcome of cardiac involvement MESHD after the patients were discharged from the hospital is yet unknown. The present study aimed to evaluate mid-term cardiac sequelae in recovered COVID-19 patients by CMRIMethods: A total of 47 recovered COVID-19 patients were prospectively recruited and underwent CMRI examination in this study. The CMRI protocol consisted of black blood SERO fat-suppressed T2 weighted imaging (BB-T2WI), T2 star mapping, left ventricle cine imaging, pre- and post-contrast T1 mapping, and late gadolinium enhancement (LGE). Myocardium edema MESHD edema HP and LGE were assessed in recovered COVID-19 patients. The left ventricle ( LV MESHD) and right ventricle (RV) function and LV mass were assessed and compared with normal controls.Results: Finally, 44 recovered COVID-19 patients and 31 normal controls were included in this study. No edema HP edema MESHD was observed in any patient. LGE was found in 13 patients. All LGE lesions were located in the middle myocardium and/or sub-epicardium with a scattered distribution. Further analysis showed that LGE-positive patients had significantly decreased left ventricle peak global circumferential strain (LVpGCS), right ventricle peak global circumferential strain (RVpGCS), right ventricle peak global longitudinal strain (RVpGLS) as compared to non-LGE patients (p<0.05), while no difference was detected between the non-LGE patients and normal controls.Conclusion: Myocardium injury MESHD existed in about 30% of COVID-19 patients. These patients had peak right ventricle strain that decreased at the 3-month follow-up. Cardiac MRI can monitor the COVID-19-induced myocarditis HP myocarditis MESHD progression, and CMR strain analysis is a sensitive tool to evaluate the recovery of left ventricle circumferential contraction dysfunction MESHD and right ventricular dysfunction MESHD.

    The Spectrum of Cardiovascular Complications MESHD in COVID-19- A Comprehensive Literature Review

    Authors: Raja Shakeel Mushtaque; Rabia Mushtaque; Shahbano Baloch; Aadil Raza; Haseeb Bhatti; Zohaib Khan

    id:10.20944/preprints202008.0257.v1 Date: 2020-08-11 Source: Preprints.org

    A newly identified novel coronavirus named as severe acute respiratory syndrome MESHD-related coronavirus2 (SARS‐CoV 2) has given rise to the global pandemic. SARS-CoV2 which causes coronavirus disease MESHD 2019 (COVID-19), is a positive-stranded RNA virus with nucleocapsid. It binds to host angiotensin-converting enzyme2 (ACE2) receptor through surface glycoprotein (S protein). These ACE 2 receptors are attached to the cell membranes of many organs. Thus, COVID-19 does not only result in acute respiratory distress syndrome MESHD respiratory distress HP syndrome but also affects multiple organ systems, requiring a multidisciplinary approach to manage this disease. COVID-19 can damage the myocardial cells and result in fulminant myocarditis HP myocarditis MESHD, acute cardiac injury MESHD, cardiomyopathy HP cardiomyopathy MESHD, heart failure MESHD, cardiogenic shock HP cardiogenic shock MESHD, or arrhythmia HP arrhythmia MESHD. COVID-19 seeds harmful immune response through cytokine storm leading to indirect organ damage. In this literature review, the available data is comprehended regarding cardiovascular complications in COVID-19, and the correlation of biomarkers with the disease activity is discussed. This literature review also highlights the important treatment options and outcomes of the individual study.

    Association Between Antecedent Statin Use and Decreased Mortality in Hospitalized Patients with COVID-19

    Authors: Aakriti Gupta; Mahesh V. Madhavan; Timothy J. Poterucha; Ersilia M. DeFilippis; Jessica A. Hennessey; Bjorn Redfors; Christina Eckhardt; Behnood Bikdeli; Jonathan Platt; Ani Nalbandian; Pierre Elias; Matthew J. Cummings; Shayan N. Nouri; Matthew Lawlor; Lauren S. Ranard; Jianhua Li; Claudia Boyle; Raymond Givens; Daniel Brodie; Harlan M. Krumholz; Gregg W. Stone; Sanjum S. Sethi; Daniel Burkhoff; Nir Uriel; Allan Schwartz; Martin B. Leon; Ajay J. Kirtane; Elaine Y. Wan; Sahil A. Parikh

    doi:10.21203/rs.3.rs-56210/v1 Date: 2020-08-09 Source: ResearchSquare

    The coronavirus disease MESHD 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), can result in a hyperinflammatory state, leading to acute respiratory distress HP respiratory distress MESHD syndrome ( ARDS MESHD), myocardial injury MESHD, and thrombotic complications MESHD, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections MESHD and ARDS, but their benefit has not been assessed in COVID-19. Thus, we sought to determine whether antecedent statin use is associated with lower in-hospital mortality in patients hospitalized for COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1st through May 12th, 2020 with study period ending on June 11th, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline socio-demographic and clinical characteristics, and outpatient medications. The primary endpoint included in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, demographic, baseline, and outpatient medication information were well balanced. Statin use was significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.48, 95% CI 0.36 – 0.64, p<0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 was associated with lower inpatient mortality. Randomized clinical trials evaluating the utility of statin therapy in patients with COVID-19 are needed.

    Clinical Features of Hemodialysis (HD) patients confirmed with Coronavirus Disease MESHD 2019 (COVID-19): a Retrospective Case-Control Study

    Authors: Xiaohui Wang; Huan Zhou; Xiaofen Xiao; Xianhua Tan; Xin Zhang; Yong He; Jing Li; Guosheng Yang; Mingmei Li; Duan Liu; Shanshan Han; Haibo Kuang

    doi:10.1101/2020.07.06.20147827 Date: 2020-07-10 Source: medRxiv

    Background: Since December 2019, Coronavirus Disease MESHD 2019(COVID-19) occurred in wuhan, China, and outbreaked rapidly into a global pandemic. This current poses great challenges to hemodialysis (HD) patients. Objective: To make a comprehensive evaluation and comparison between HD patients confirmed with COVID-19 and the general HD patients. Methods: HD patients confirmed with COVID-19 in Wuhan No.5 Hospital were admitted as confirmed group from Jan 10 to Mar 15, 2020. And HD patients not infected in our dialysis center were chosen as control group. General characteristics, laboratory indicators were retrospectively collected, analyzed and compared. Results: A total of 142 cases were admitted, including 43 cases in confirmed TRANS group and 99 in control group. Body mass index (BMI) was slightly lower in confirmed group than that in control group (P=0.011). The proportion of one or less underlying disease in confirmed group(51.16%) was higher than that in control group(14.14%)(P< 0.001), and the proportion of three or more underlying diseases in confirmed group(11.63%) was lower than that in control group(52.53%)(P< 0.001). Patients in confirmed group exhibited significantly lower hemoglobin, lymphocyte count, and lymphocyte percentage, but higher neutrophil percentage, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein, aspartate transaminase, and alkaline phosphatase. There was no significant difference in age TRANS, gender TRANS, dialysis age TRANS, primary disease MESHD, the using of ACEI/ARB, platelet-to-lymphocyte ratio (PLR) , and other indicators between the two groups. Conclusions: Faced with Severe Acute Respiratory Syndrome-CoV-2 MESHD (SARS-CoV-2), HD patients with lower BMI and hemoglobin were more susceptible to be infected MESHD, which might be related to malnutrition HP. Once confirmed with COVID-19, HD patients expressed obviously disregulated in inflammation MESHD and immune.

    Risk factors associated with failure of high-flow nasal cannula oxygen therapy in patients with severe COVID-19 in Wuhan, China

    Authors: Xiao-huan Ma; Fang Yin; Jie Zhang; Meng-yun Peng; Hong Guan; Ping Gong

    doi:10.21203/rs.3.rs-37538/v1 Date: 2020-06-22 Source: ResearchSquare

    Background Acute hypoxemic respiratory failure MESHD respiratory failure HP is prevalent in severe Coronavirus Disease MESHD 2019 (COVID-19). High-flow nasal canula (HFNC) is currently the most common ventilation strategy for COVID-19 patients with respiratory failure HP respiratory failure MESHD. This study is to analyze the risk factors associated with high-flow nasal canula (HFNC) oxygen therapy failure MESHD in patients with severe COVID-19.Methods: In this single-center, retrospective, observational study, we enrolled patients with confirmed severe COVID-19 admitted to Renmin Hospital of Wuhan university (Wuhan, China) from 1 February 2020 to 26 March 26 2020. Epidemiological, clinical, and laboratory data, and treatments and outcomes upon hospital admission, were obtained from electronic medical records. Sequential organ failure assessment (SOFA) scores were calculated.Results: Of 54 patients with severe COVID-19, HFNC was successful in 28 (51.9%) and unsuccessful in 26 (48.1%). HFNC failure MESHD was seen more commonly in patients aged TRANS ≥60 years and in men. In addition, compared with patients successfully treated with HFNC, patients with HFNC failure MESHD had the following characteristics: higher percentage of fatigue HP fatigue MESHD and anorexia HP anorexia MESHD as well as cardiovascular disease MESHD; increased time from onset to diagnosis and SOFA scores; elevated body temperature, respiratory rate, and heart rate; more complications including ARDS, septic shock MESHD shock HP, myocardial damage MESHD, and acute kidney injury HP acute kidney injury MESHD; increased neutrophil counts and prothrombin time; and decreased HP arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) (all P < 0.05). However, binary logistic regression analysis showed that only male TRANS gender TRANS and PaO2/FiO2 were independent risk factors significantly associated with HFNC failure MESHD (both, P < 0.05). Conclusion: Patients with severe COVID-19 had a high HFNC treatment failure rate. Male TRANS gender TRANS and decreased PaO2/FiO2 were independent risk factors associated with HFNC failure MESHD in severe COVID-19 patients.

    Cardiovascular Risk Factors and Evolution of Patients Attended with COVID-19 in a National Reference Hospital from Lima, Peru MESHD

    Authors: Germán V. Valenzuela; Alfonso J. Rodriguez-Morales; Roxana Mamani; Ricardo Ayala; Katherine Pérez; Cynthia Sarmiento; Jessica Calcino; Luis García; José Amado

    id:10.20944/preprints202006.0237.v1 Date: 2020-06-19 Source: Preprints.org

    Coronavirus disease 2019 (COVID-19) fatal outcomes have been associated with multiple cardiovascular risk factors. In new epidemic areas, such as Latin America, there is a lack of studies about this. Here, we evaluated those factors in a retrospective cohort of patients in a national reference hospital of Lima, Peru. Design. A retrospective cohort observational study was done. For this study, information was obtained from clinical records of the hospital for the cases that were laboratory-diagnosed and related, during March 6th and April 30th, 2020. rRT-PCR was used for the detection of the RNA of SARS-CoV-2 following the protocol Charité, Berlin, Germany, from nasopharyngeal swabs at the National Institute of Health. Calculation of the odds ratio (OR) with the respective 95% confidence interval (95% CI) was done, also logistic regression for adjusted OR (multivariate) was done. Values of p < 0.05 were considered significant for all analyses. Results. One hundred six hospitalized patients were evaluated. The mean age TRANS of patients was 61.58 years (SD 16.81). Cardiovascular risk factors among them were hypertension HP hypertension MESHD (46.2%), diabetes MESHD (28.3%), and obesity HP obesity MESHD (28.3%), among others. Fifty-six patients died (52.8%). Mortality associated factors at the multivariate analysis were arterial hypertension HP hypertension MESHD (OR=1.343, 95% 1.089-1.667), myocardial injury MESHD (OR=1.303, 95% 1.031-1.642), and mechanical ventilation (OR 1.262, 95% 1.034-1.665), as associated factors. Conclusion. As observed in other regions of the world, cardiovascular risk factors represent a significant and independent threat to be considered in patients with COVID-19. Further studies and interventions in Peru and Latin America are expected.

    Myocardial Injury MESHD at Early Stage and Its Association with Death Risk of Patients with COVID-19: A Hospital-Based Prospective Case-Cohort Study

    Authors: Lin Fu; Xiu-Yong Li; Jun Fei; Ying Xiang; Hui-Xian Xiang; Meng-Die Li; Fang-Fang Liu; Ying Li; Hui Zhao; De-Xiang Xu

    doi:10.21203/rs.3.rs-34902/v1 Date: 2020-06-12 Source: ResearchSquare

    Background: There are growing evidence demonstrating that coronavirus disease MESHD 2019 (COVID-19) is companied by acute myocardial injury MESHD. However, the association of SARS-CoV-2-induced myocardial injury MESHD with death risk of COVID-19 is unclear.Methods: This prospective case-cohort study analyzed 355 COVID-19 patients from two hospitals in different regions. Clinical and demographic information were collected. Myocardial injury MESHD was evaluated and its prognosis was followed up. Results: Of 355 hospitalized patients with COVID-19, 213 were mild, 90 severe and 52 critically ill MESHD patients. On admission, 220 (62.0%) patients were with myocardial injury MESHD. Myocardial injury MESHD was more popular in critically ill MESHD patients. Using multivariate logistic regression, male TRANS, older age TRANS and comorbidity with hypertension HP hypertension MESHD were three crucial independent risk factors predicting myocardial injury MESHD of COVID-19 patients. Among 220 COVID-19 patients with myocardial injury MESHD, 33 (15.0%) died on mean 10.9 day after hospitalization. Mortality was increased among COVID-19 patients with myocardial injury MESHD (15.0% vs 1.74%, RR=8.625, P<0.001). Follow-up study observed that at least one myocardial index of 21.3% patients remained abnormal 14 days after discharge. Conclusion: Myocardial injury MESHD at early stage elevates mortality of COVID-19 patients. Male TRANS elderly TRANS patients with hypertension HP hypertension MESHD are more vulnerable to myocardial injury MESHD. SARS-CoV-2-induced myocardial injury MESHD has not completely recovered 14 days after discharge.

    Life-threatening cardiogenic shock HP cardiogenic shock MESHD in a pediatric patient with SARS-CoV-2-associated myocarditis HP myocarditis MESHD treated with remdesivir: a case description and report of similar cases from the Literature

    Authors: Silvia Molinari; Lucia M.D. Colasanto; Maria L. Melzi; Alessandro Cattoni; Roberto Panceri; Michela Bombino; Giuseppe Lapadula; Andrea Biondi

    doi:10.21203/rs.3.rs-34802/v1 Date: 2020-06-12 Source: ResearchSquare

    BackgroundChildren are relatively spared from Coronavirus disease MESHD 2019 (COVID-19), but some severe cases have been reported. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in children TRANS may affect the cardiovascular system. We hereby report about a case of myocarditis HP myocarditis MESHD evolving to cardiogenic shock HP cardiogenic shock MESHD in a SARS-CoV-2 positive child TRANS.Case presentationAn otherwise healthy 12-year-old patient was admitted with fever HP fever MESHD, vomiting HP vomiting MESHD, diarrhoea and drowsiness MESHD drowsiness HP, without any respiratory symptoms. He was diagnosed with COVID-19 on nasopharyngeal swab. He developed hypotension HP hypotension MESHD and cardiogenic shock HP cardiogenic shock MESHD. Bedside echocardiography revealed left ventricular impairment MESHD with an ejection fraction (LVEF) below 25%. Plasmatic markers of myocardial injury MESHD were remarkably raised, as well as inflammatory biomarkers, including procalcitonin (highest recorded value: 66 ng/mL) and interleukin-6 (8209 pg/mL). The child TRANS was transferred to Intensive Care Unit and he was treated with catecholamine support, mechanical ventilation and empiric anti-infectious therapy, including broad spectrum antibiotics and the antiviral agent remdesivir. All additional microbiological investigations yielded negative results. We observed a gradual improvement of LVEF within 5 days. A cardiac magnetic resonance confirmed the suspicion of myocarditis HP myocarditis MESHD. After 21 days of hospitalisation, the child TRANS was discharged without sequelae.ConclusionsOur hypothesis is that the child TRANS suffered from SARS-CoV-2-induced fulminant myocarditis HP myocarditis MESHD, probably in the setting of cytokine release syndrome (CRS). The peculiarity of this SARS-CoV-2 infection MESHD is the presence of cardiac failure MESHD in a previously healthy child TRANS without a respiratory illness MESHD. The positive outcome is in line with published Literature about the overall better prognosis of COVID-19 children TRANS compared to adults TRANS. Remdesivir, an investigational antiviral therapy, may have played a role on the clinical improvement of the child TRANS.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.